Floatz logo

11 assets in Epstein-Barr Virus Infection

Therapeutic assets addressing Epstein-Barr Virus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Rituximab
Epstein-Barr Virus Infection
Jennifer AmengualP2BB (67)
L-Dep
Epstein-Barr Virus Infection
Beijing Friendship HospitalP3B (60)
Nivolumab
Epstein-Barr Virus Infection
National Cancer Institute (NCI)P2CCC (53)
Tabelecleucel
Epstein-Barr Virus Infection
Pierre Fabre MedicamentP2CCC (53)
Adenovirus Specific T- Lymphocytes
Epstein-Barr Virus Infection
Jessie L. AlexanderP1/2CCC (48)
Epstein-Barr Virus Specific T-Lymphocytes
Epstein-Barr Virus Infection
Jessie L. AlexanderP1/2CCC (48)
Star0602
Epstein-Barr Virus Infection
Marengo Therapeutics, Inc.P1/2CCC (48)
Cytomegalovirus -Specific Cytotoxic T Cells
Epstein-Barr Virus Infection
Jessie L. AlexanderP1/2CC (47)
Icaspase9-Transduced T Cells
Epstein-Barr Virus Infection
Baylor College of MedicineP1CC (43)
Rimiducid
Epstein-Barr Virus Infection
Baylor College of MedicineP1CC (43)
VK2019
Epstein-Barr Virus Infection
Pierluigi PorcuP1NR ()